SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- On July 25, 2025, investors in Hims & Hers Health, Inc. (NYSE: HIMS) saw the price of their shares significantly fall during intraday trading on reports that U.S. lawmakers urged the FDA to act against copycat versions of weight loss drugs, citing safety concerns. This latest development follows an announcement by Novo Nordisk on June 23, 2025, the Danish maker of the FDA-approved weight-loss medication Wegovy® (a GLP-1 treatment for obesity), that it termina ...